Evidence map›Paper›PMID 29209041›Full record

ArticleLeukemia2018

The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.

A G Sanarico, C Ronchini, A Croce, E M Memmi, U A Cammarata, A De Antoni, S Lavorgna, M Divona, L Giacò, G E M Melloni and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. The WWP1-JARID1B axis sustains acute myeloid leukemia chemoresistance.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. The roles of ubiquitination in AML.Annals of hematology · 2024
    Review
  9. Article
  10. Article
  11. Portrait of WWP1: the current state in human cancer.Frontiers in cell and developmental biology · 2024
    Review
  12. Review
  13. Review
  14. The dual role of autophagy in acute myeloid leukemia.Journal of hematology & oncology · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

A G SanaricoDepartment of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
C RonchiniCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia, Milan, Italy.ORCID 0000-0003-3908-4021
A CroceDepartment of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
E M MemmiDepartment of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
U A CammarataDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy.
A De AntoniThe FIRC Institute of Molecular Oncology Foundation-IFOM, Milan, Italy.
S LavorgnaDepartment of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
M DivonaDepartment of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
L GiacòDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy.
G E M MelloniCenter for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia, Milan, Italy.
A BrendolanDivision of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy.
G SimonettiDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
G MartinelliDepartment of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
P MancusoLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
F BertoliniLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
F Lo CocoDepartment of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
G MelinoDepartment of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
P G PelicciDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy.
F BernassolaDepartment of Experimental Medicine and Surgery, University of Rome 'Tor Vergata', Rome, Italy.
University of Rome Tor Vergata · ITEuropean Institute of Oncology · ITItalian Institute of Technology · ITUniversity of Bologna · ITIFOM · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

European Research Council 341131Medical Research Council MC_U132670600
6 · The paper itself

Abstract

The E3 ubiquitin ligase (E3) WWP1 is an oncogenic factor implicated in the maintenance of different types of epithelial cancers. The role of WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) in haematological neoplasms remains unknown. Acute myeloid leukaemia (AML) is characterized by the expansion of malignant myeloid cells blocked at different stages of differentiation. Here we report that the expression of WWP1 is significantly augmented in a large cohort of primary AML patients and in AML cell lines, compared with haematopoietic cells from healthy donors. We show that WWP1 inactivation severely impairs the growth of primary AML blasts and cell lines in vitro. In vivo, we observed a reduced leukaemogenic potential of WWP1-depleted AML cells upon transplantation into immunocompromised mice. Mechanistically, WWP1 inactivation induces the accumulation of its protein substrate p27

Indexed as

AnimalsCell Cycle CheckpointsCell DifferentiationCell Line, TumorCell ProliferationCell SurvivalCyclin-Dependent Kinase Inhibitor p27G1 PhaseGene Expression Regulation, NeoplasticHumansLeukemia, Myeloid, AcuteMiceResting Phase, Cell CycleSignal TransductionU937 CellsUbiquitinationCyclin-Dependent Kinase Inhibitor p27Ubiquitin-Protein LigasesWWP1 protein, human

Identifiers

PMID29209041
PMCPMC5886071
OpenAlexW2772043274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.